

Amended Claims:

Please amend the claims as follows:

3. (Twice amended) The method according to claim [1] 12, claim [5] 13, claim [6] 14, or claim 7, wherein said cancer comprises a lymphoma.

4. (Twice amended) The method according to claim [1] 12, claim [5] 13, claim 6 14, or claim 7, wherein said cancer comprises a breast cancer.

7. (Amended) The method according to claim [5] 13 or claim [6] 14, wherein said infusion [of step (b)] is continuous over said 96 hour period.

8. (Amended) The method according to claim [5] 13 or claim [6] 14, further comprising: repeating said 96 hour infusion [of step (b)] every 21 days.

9. (Amended) The method according to claim 7, further comprising: [(c)] repeating said 96 hour infusion [of step (b)] every 21 days.

10. (Amended) The method according to claim [1] 12, wherein in said infusion step [(b)], the period of infusion is for [at least] 96 hours.

11. (Amended) The method according to claim 10, further wherein said infusion [of] step [(b)] is continuous over said 96 hour period.

New Claims:

Please add the following new claims 12-14:

3

12. (New) A method of treating a patient suffering from lymphoma or breast cancer, comprising infusing into said patient a taxol infusion solution containing a concentration of taxol sufficient to provide between 17.5 and 35 milligrams of taxol per square meter of patient surface area over a period of 24 hours, and administering said infusion solution to said patient over said 24 hour time period.

13. (New) A method of treating a patient suffering from lymphoma or breast cancer, comprising infusing into said patient a taxol infusion solution containing a concentration of taxol sufficient to provide between 70 and 140 milligrams of taxol per square meter of patient surface area over a period of 96 hours, and administering said infusion solution to said patient over said 96 hour time period.

14. (New) A method of treating a patient suffering from lymphoma or breast cancer, comprising: infusing into said patient a taxol infusion solution containing a concentration of taxol sufficient to provide between 17.5 and 35 milligrams of taxol per square meter of patient surface area per 24 hours, and administering said solution to said patient over a 96 hour period of infusion time.

REMARKS

In this Amendment, Applicants have cancelled claims 1, 5, and 6, and replaced the cancelled claims with new claims 12, 13, and 14, respectively. Claims 3, 4, and 7-11 have been amended. It is respectfully submitted that no new matter has been added in the amended and new claims.